StreetInsider.com News Articles

Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications

Thu, 28 May 2026 10:59:00 -0400

HOUSTON, TEXAS - May 28, 2026 (NEWMEDIAWIRE) - Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced that its gene synthesis and cell-free protein expression workflow was used in a recent study by Tencent AI for Life Sciences Lab published in Nature Communications , enabling rapid experimental validation of AI-designed proteins with improved activity, stability, and multifunctionality.

Bridging AI Protein Design and Experimental Validation

Artificial intelligence has significantly accelerated protein amino acid sequence design, however, translating these computational designs into functional proteins remains a key challenge in protein engineering. Protein activity, stability, folding, and expression are influenced by complex structural

Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications

Thu, 28 May 2026 10:59:00 -0400

Bridging AI Protein Design and Experimental Validation

Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications

Thu, 28 May 2026 10:59:00 -0400

Bridging AI Protein Design and Experimental Validation

Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications

Thu, 28 May 2026 10:59:00 -0400

Bridging AI Protein Design and Experimental Validation

Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Tue, 19 May 2026 11:45:00 -0400

Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening

HOUSTON, May 19, 2026 /PRNewswire/ -- Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, is proud to announce the launch of its innovative XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), a cutting-edge solution designed to supercharge artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery.

Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Tue, 19 May 2026 11:45:00 -0400

Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening

Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Tue, 19 May 2026 11:45:00 -0400

Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening

Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Tue, 19 May 2026 11:45:00 -0400

Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening

Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Tue, 19 May 2026 11:45:00 -0400

Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening

Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Tue, 19 May 2026 11:45:00 -0400

Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening

Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Tue, 19 May 2026 11:45:00 -0400

Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening

Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Tue, 19 May 2026 11:45:00 -0400

Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening

Sino Biological Launches XPressMAX(TM) Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Mon, 18 May 2026 12:01:00 -0400

Ultra-Fast Protein /Antibody Synthesis in 3 Hours , Speed Up AI-Powered HTP Screening

HOUSTON, TEXAS - May 18, 2026 (NEWMEDIAWIRE) - Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, is proud to announce the launch of its innovative X P ressMAXTM Cell-Free Protein Synthesis Kit (Cat#: CFKIT02) , a cutting-edge solution designed to supercharge artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery.

X P ressMAXTM Cell-Free Protein Synthesis Kit

The novel kit leverages advanced cell-free protein synthesis technology to enable rapid, efficient in vitro production of target proteins and antibodies - eliminating the

Sino Biological Launches XPressMAX(TM) Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Mon, 18 May 2026 12:01:00 -0400

Ultra-Fast Protein /Antibody Synthesis in 3 Hours , Speed Up AI-Powered HTP Screening

X P ressMAXTM Cell-Free Protein Synthesis Kit

The novel kit leverages advanced cell-free protein synthesis technology to enable rapid, efficient in vitro production of target proteins and antibodies - eliminating the

Sino Biological Launches XPressMAX(TM) Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Mon, 18 May 2026 12:01:00 -0400

Ultra-Fast Protein /Antibody Synthesis in 3 Hours , Speed Up AI-Powered HTP Screening

X P ressMAXTM Cell-Free Protein Synthesis Kit

The novel kit leverages advanced cell-free protein synthesis technology to enable rapid, efficient in vitro production of target proteins and antibodies - eliminating the

Sino Biological Launches XPressMAX(TM) Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Mon, 18 May 2026 12:01:00 -0400

Ultra-Fast Protein /Antibody Synthesis in 3 Hours , Speed Up AI-Powered HTP Screening

X P ressMAXTM Cell-Free Protein Synthesis Kit

The novel kit leverages advanced cell-free protein synthesis technology to enable rapid, efficient in vitro production of target proteins and antibodies - eliminating the

Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains

Tue, 03 Mar 2026 20:53:00 -0400

HOUSTON, March 3, 2026 /PRNewswire/ -- The World Health Organization (WHO) has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A(H3N2) subclade K and emerging B/Victoria lineage strains. In rapid response, Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has launched the 2026-2027 Northern Hemisphere influenza vaccine strain antigens to accelerate vaccine development.